{"title": "PDF", "author": "PDF", "url": "https://synapse.koreamed.org/upload/synapsedata/pdfdata/0003trd/trd-57-125.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "12 5 Tuberculosis (TB) remains an enormous global health problem, and a new vaccine against TB more potent than the current inadequate BCG vaccine is urgently needed. We const ructed three recombinant Mycobacterium bovis BCG (rBCG) strains over -expressing antigen (Ag) 85A, Ag85B, or both of M. tuberculosis u s i n g t h e i r o w n promoter and secretory sequence, or hsp60 promoter. SDS -PAGE analysis of rBCG proteins showed over - expression of Ag85A and Ag85B proteins in higher level than of those in their parental strain of BCG. In addition, rBCG(rBCG/B.FA) over -e x p r e s s i n g A g 8 5 A a n d A g 8 5 B i n d u c e d s t r o n g I F N - production in splenocytes. However, there was no significant difference in protective efficacy betw e e n r B C G a n d t h e i r p a r e n t a l B C G s t r a i n . I n t h i s study, therefore, rBCG over -expressing Ag85A, Ag85B, or both failed to show enhanced protec tion against M. tuberculosis infection in a mouse model. ( Tub e r c Re s p i r Di s 20 04; 5 7 : 1 25- 131 ) Key words : T u b e r c u l o s i s , V a c c i n e , R e c o m b i n a n t B C G .Co n s t r u c t i o n of Re c o m b i n a n t BCG s O v er ex pr es si n g An t i g e n 85 Co m p l e x an d Th e i r Pr o t e c t i v e E ffi c a c y ag ai n s t M y co b a ct e r i u m t u ber c u l o s i s In fe c t i o n in a Mo u s e Mo d e l S e ung-H eon Lee1, Bo - Y o u n g J eon2, Y o ung-G i l Pa r k1, Hy e - Y o u n g Lee3, S a ng-N a e Ch o2, H y o- J o on Ki m4 and G ill- H a n Ba i1* 1De p a r t m e n t of M o le c u la r Bi o l o g y , Ko r e a n In s t it u t e of Tu be r c u l o s i s , Se ou l , Ko r e a 2De p a r t m e n t of Mi c r o b i o l o g y , Yon s e i Un i v e r s i t y C o lle g e of Me d i c i n e , Se o u l , Ko r e a 3De p a r t m e n t of Bi o m e d i c a l L a b o ra t o ry Sci e nc e , C o lle g e of He a l t h Sci e nc e s , Yon s e i Un i v e r s i t y , Wo n j u , Ko r e a 4De p a r t m e n t of Bi o c h e mi s t r y an d M o le c u la r B i ol og y, C o lle g e of Sci e nc e Te c h no l o gy , Ha n y a n g Un i v e r s i t y , An s a n , Ko r e a 85 BCG 1 , 2 , 3 , 4 1, 2, 1, 3, 2, 4, 1 Thi s wo r k wa s su ppo r t e d by a gr an t of th e Ko r e a He a l t h 21 R&D Pr o j e c t fro m th e Mi n i s t r y of He a l t h & We l f a r e , R e p u b lic of K o r e a . ( 03-P J 1-P G 1-21400-0001) Address for correspondence Gill -Han Bai Korean Institute of Tuberculosis14 Woomyundong, Sochogu, Seoul, 137 -140, Korea Phone : 02 -577 -5 7 6 6 F a x : 0 2 -573 -1914 E -mail : gbai@hotmail.com Received : Mar. 26. 2004. Accepted : May. 14. 2004.In tr o d u c ti o n T u ber c ul osi s (T B ) ha s b een on e of th e le a d in g in fe ct i o us di seases in th e wo r l d , and th e Wo r l d He a l t h Or g a n i z a t i o n (W H O ) est i m a t e d 80 m i llio n new ca ses of t ube r c ul o s i s in th i s de cad e1. In addi t i o n , th e em er ge n c e of dr ug -r e s i s t a nt st r a i n s of M. tu b e r c u l o s i s have em phasi z ed on ce ag a i n th a t dr ug th e r a p y has its in t r in s i c l i m i ta ti o n s . Th e onl y c u rren t l y av a i l a bl e TB v a cci ne is an a tte n u a t e d st rai n of M y co bact eri u m bo vi s , b a c i llu s C a l m e tte - G u \u00e9 ri n ( B C G ) . BC G co nt i n ues to be wi d e l y a d m i ni st er ed to chi l dr en, ye t its ef f i cacy has de m o n st rat e d va r i a b l e pr o t ect i ve ef f i caci e s ra n g i n g fro m 0 to 85% in d i f f er ent fi e l d tr ia ls2. Th u s , an im p r o v e d v a cci ne is ur gent l y need ed to rep l a c e BCG and to prev ent TB ef f e ct i v e l y. Exper i m e nt a l app r oa ches to dev e l o p an im p r o v e d v a cci ne agai nst TB hav e in c l u ded th e us e of liv e at t e nuat ed m y co ba ct er i a3, subuni t v a cci ne4- 6, rec o m b i n a n t BCG , and DNA va c c i n e7, 8. Th e pr ot ec t i ve an t i gens fo r t ube r c ul os i s ar e st i l l not preci s el y def i ned, but th e pr evai l i ng hypo t h e s i s th a t th e y pr edo m i n an t l y resi d e wi t h i n th e secret ed or ex port ed pr ot ei ns of th e b a c i llu s has b een recen t l y s u ppor t ed by obs e r v at i o n s in an i m al mo d e l9. Th e th r e e co m p onen t s of th e ant i gen (A g ) 85 co m p l e x , aSH Le e, et al . : Co n s t r u c t i o n of re c o m b i n a n t BC G s ov e r ex pr es s i ng ant i gen 85 co m p l e x and th e i r pr ot ec t i v e 12 630- to 32- k i lo d a lt o n fa m i l y of pr o t ei n s ( A g 85A , Ag 85 B , an d Ag 8 5 C ) , c o n s ti tu te a ma j o r f r act i on ( 2 0- 30 % ) of th e secret ed pr o t ei ns in th e cul t ur e fil t r a te (C F )10. Ag 8 5 ho m o l o gue s ar e fo u n d in al l m y co ba ct eri a l speci e s. Th e Ag 8 5 co m p l e x in d u c e s st ron g T- c e l l p r o l if e r a t io n , in t e r f e r o n - (IF N - ) p r od uc t i on and c y to to x i c T ly m p h o c y t e (C T L ) act i v i t y in mo s t he al t h y i n di v i du al s in f e c t e d wi t h M. tu b e r c u l o s i s or M. le p r a e11. S e n s itiz a t io n wi t h Ag 8 5 co m p l e x oc cur s in th e fi rs t pha s e of m y co bact er i a l in f e c t io n12. He n c e , r e c o g n itio n of th e s e ant i gens ma y be an ef f e ct i v e st r a t e gy of th e host to co nt r o l in itia l bact er i a l rep l i cat i on, con s equent l y ma k i n g th e pr o t ei n s of th e Ag 8 5 co m p l e x re a s o n a b l e v a cci ne ca ndi d at es . In th e pr es ent st ud y, we hav e c o n s tr u c te d th re e rB C G st rai n s ov er- e x p res s i n g on l y A g 85A , A g 85B , or bot h and eval uat e d th e i r i m m u nog e ni ci t y and pr ot ec ti v e e ffi c a c y ag a i n s t M. tu b e rc u l o s i s in f e c t io n in a mo u s e mo d e l . Ho w e v e r th e enh a nce d in vi t r o i mmu no l o gi ca l r e spo n se of th e re c o m b i n a n t va c c i n e, rB C G / B. FA , af f o r d no gr eat e r pr o t ect i on ag a i nst M. tu b e r cu l o si s in fe c t io n . Ma t e r i a l s and Me t h o d s 1. Bac t e r i a M. tu b e r c u l o s i s H 37R v and M. bo vi s BCG Pa st e u r 1173P 2 th a t ha d been m a in ta in e d at th e Ko r e a n In s t i t u t e of Tu b e r c u l o s i s we r e us ed in th i s st ud y. M. tu b e r c u l o s is Er d m a n st r a i n wa s pr o v i d ed by P. J . B r ennan (C o l o r a d o St a t e Un i v e r s i t y , Fo r t Co l l i n s , Co . , U. S . A. ) . Al l m y cobact er i a we r e m a in t a in e d in Og a w a me d i a . E. c o l i JM 109 wa s us ed fo r cl o n i n g . 2. P r e p a r a t i o n of cu l t u r e f ilt r a t e pr ot ei n( C F P ) Cu l t u r e fil t ra te pr o t e i n (C F P ) fro m M. tu b e r c u l o s i s wa s pr o v i d ed by De p a r t m e n t of Mi c r o b i o l o g y , Yo n s e i Un i v e r s i t y C o lle g e of Me d i c i n e . Cu l t u r e fil t ra te pr o t e i n wa s pur i f i ed fro m M. tu b e rcul o si s . M. tu b e r c u l o s is bact er i a ( 2 \u00d7 1 06 CF U/ m l ) we r e gr o w n in mo d i f i e d Sa u t o n me d i u m wi t h o u t T w een8 0 on an or bi t a l shaker fo r 7 days. Th e cul t ur e su p e r n at an t s we r e st er i l e f i l t ered and concent r at ed by u l tr a f i l tra t i o n , over an Ami c o n u l tr a f ilt r a t io n s t i rred cel l (A m i c o n , Da n v e r s , MA , US A) fitte d wi t h a PM 10 me m b r a n e ( M illip o r e , B e df or d, MA , USA) . Th e to ta l pr o t ei n co ncent r at i o n wa s e s ti m a te d by th e bi ci ncho ni ni c aci d pr o t ei n assay (P i e rc e , Ro c k f o r d , IL , US A) . 3. C o n s tr u c ti o n of th e pl as m i ds Th e pl asm i d pE M th a t wa s pr o v i d ed by Hy e - Yo u n g Le e (Y o n s e i Un i v e r s i t y , Wo n j u , Ko r e a )13, an Es c h e r i c h i a co l i -M yco b act e ri u m s h u ttl e ex pressi on pl asm i d, wa s em pl oyed fo r over -ex p r e ss i o n of M. tu bercul o s i s ge n e s in BCG . Th e pl a s m i d pEM wa s eng i neered to expr es s rec o m b i n a n t A g 85A of M. bovi s BC G and A g 85B of M. tu b e r c u l o s i s fro m it s ow n pr o m ot er and hs p60 p r om ot er. Ge n e s enc o d i ng A g 85A fr o m M. bo vi s BCG and A g 85B fr o m M. tu b e r c u l o s i s we r e a m p l ifie d by PC R usi n g pr i m er s co n t ai ni ng Ba m HI or Spe I. Af t e r cl oni n g in to pT 7B l u e T- v e c t o r (N o v a g e n , Ma d i s o n , WI , USA) , a m p l ifie d DNA s we r e di g e st e d wi t h Ba m HI or Sp e I and li g a t e d to Ba m HI or Sp e I- d i g e ste d pEM . Th e o r ie n t a t io n of A g 85A and A g 85B ge n e in s e r t s we r e th e n co nf i r m e d by re s t r i c t i o n enz y m e di g e st i o n. Th e rec o m b i n a n t pl as m i ds we r e in tr o d u c e d by el ect r oporat i o n in to BCG Past eu r 11 73P 2 . Re c o m b i n a n t st r a i n s we r e m a in ta in e d in Mi d d l e b r o o k 7H 11 ( M 7H 11) agar (D i f c o , Sp a r k s , MD , US A) me d i u m c o nt a i ni ng ka n a m y ci n at con c en tr a t io n of 25 g/ m l . Th e ex pressi on an d ex por t of re c o m b i n a n t pr o t ei ns we r e ve r i f i e d by SDS - P A GE. 4. Pr e p a r a t i o n of i mmu n i z a t i o n in o c u l a Wi l d ty p e BC G and rB C G s we r e cul t ur ed on Sa u t o n me d i u m at 37 as unshaken cul t ur es. Ka n a my c i n 25 g/ m l wa s adde d to rB C G cul t ur es. Th e sur f ac e pel l i c l e s we r e col l ect e d and di sr u p t e d wi t h 6 mm gl a s s Tu b e r c u l o s i s and Re s p i r a t o r y Di s e a s e s Vo l . 57. No . 2, Au g , 2004 12 7Fi g u r e 1 .S D S - F A G E anal ysi s of cu l t u r e filtr a te pr ot ei n of re c o m b i n a n t BCG s . Lane 1, m o le c u la r w e i ght st an d a r d ; la n e 2, BC G ; la n e 3, rB C G /F A ; la n e 4, rB C G / F B ; la n e 5, rB C G / B . F A . P r ot ei n bands we r e v i s u a liz e d by C oom as s i e bl ue s t ai ni ng. bead s by gent l e vor t e x i n g. Vi a b l e org a n i s m s we r e co unt e d by pl a t i n g ser i al di l u t i o n s on M7 H 1 1 agar (D i f c o , Sp a r k s , MD , US A) . 5. I mmu n i z a t i o n of an i m al s S p e c ific pat h ogen-f r e e fe m a l e C 57B L / 6 mi c e we r e pur c has e d fro m Ja p a n SLC , In c. Shi j u o k a , Jap a n . Gr o u p s of ei g h t mi c e each in je c t e d su bcut aneou s l y wi t h a si ng l e dose of BC G an d rB C G s [2 \u00d7 1 05 co l o ny fo rm i n g uni t (C F U )/m o u s e ] . Ne g a t i v e co n t rol s we r e in je c t e d su bc ut a n eo us l y wi t h 200 l of st eri l e, pyr o ge n - f r e e sa l i ne. Al l mi c e use d we r e 6- to 7- we e k s of age an d we r e ho us ed in ca g e s co nt a i ned wi t h i n a BL- 3 bi ohazar d ani m al ro o m at Yo n s e i Un i v e r s i t y Me d i c a l Re s e a r c h Ce n t e r . An i m a l s we r e a llo w e d fre e ac cess to wa t e r and st andar d mo u s e cho w . 6. Me a s u r e m e n t of IF N - pr oduct i on Fo u r we e k s af t e r im m u n i z a t i o n , i mmu n i z e d or co n tro l mi c e we r e s a c r if ic e d , and th e i r spl e ens we r e rem o v e d a s e p t i c a lly . Th e sp l eens fro m th re e mi c e we r e po ol ed in ea ch gr o u p . Sp l e e n c e lls (2 \u00d7 1 05 c e lls / w e ll) we r e cul t ur ed in 96-w e l l cel l cul t ur e pl at es (N u n c , Ro s k i l d e , De n m a r k ) in R P M I 1640 suppl e m e nt ed wi t h 50 M 2- m e rcap t o et hanol , 1% peni ci l l i n- st rep t om yc i n , 1 mM g l ut am at e and 10% (v /v ) fe ta l ca l f ser u m . Th e cul t ur e fil t r a te pr o t ei n( C F P) we r e ad ded to th e w e lls at a fi n a l co ncent r a t i o n of 10 g/ m l . S u per n at ant we r e har v es t e d af t e r 6 days in c u b a t i o n at 37 in a hum i di f i e d CO 2 . M e asurem ent of IF N - wa s pe r f o r m e d wi t h a mo u s e IF N - Op t E I A TM Se t (P h a rm i n g e n , Sa n Di e g o , CA , US A ) . 7. C h a lle n g e in f e c t io n Si x we e k s af t e r im m u n i z a t i o n , fiv e mi c e in each gr o u p we r e c h a lle n g e d wi t h an aer o so l ge n e r a t e d fr o m a 10 ml , si n g l e - c el l suspensi on cont ai ni ng a to t a l of 5\u00d7 105 CFU of M. tu b e r c u l o s is Er d m a n st r a i n . Th e s e aer o so l dose s de l i v e r e d appr o x i m at el y 200 liv e baci l l i to th e lu n g s . Mi c e we r e sa cr i f i c ed 4 we e k s af t e r c h a lle n g e . Th e sp l eens an d lu n g s we r e rem o v e d a s e p tic a lly an d cul t ur ed fo r CF U of M. tu b e rc u l o s i s . D i f f erences in CF U bet w een gr o u ps we r e an a l y z ed s t a t is t i c a lly by th e St u d e n t ' s t- te s t . Re s u l t s 1 . E x p r essi o n of A g 85A an d Ag 8 5 B fr o m rB C G s Th r e e rec o m b i n a n t BC G s ex p r essi ng an d secr et i n g 35kDa1 saline FA GroupIFN-r (pg/ml)CFPSH Le e, et al . : Co n s t r u c t i o n of re c o m b i n a n t BC G s ov e r ex pr es s i ng ant i gen 85 co m p l e x and th e i r pr ot ec t i v e 12 8Fi g u r e 2 . I F N - pr odu c t i on by sp l e n o cyt e s of im m u n i zed mi c e . C5 7 B L / 6 mi c e we r e im m u n i z e d subc ut aneo usl y wi t h 200 l of sal i ne or 2\u00d7 105 CF U of FA (r B C G / F A ), FB (r B C G / F B ), B. FA (r B C G / B . F A ), or BC G . Th r e e mi c e per gr oup we r e sacr i f i c ed a fte r 4 we e k s . Sp l e n o c y t e s we r e cu l t u r e d wi t h cul t ur e filtr a te pr ot e i n (1 0 g/ m l ) of M. tu b e r c u l o s is H3 7 R v . Su p e r n a t a n t s we r e har v es t e d a fte r 6 day s of in c u b a ti o n fo r IF N - a ssa y . Da t a r e pr esent th e me a n and st andar d er r o r of th r e e mi c e pe r gr oup. ( ) : IF N - co ncent r at i o n( pg/ m l ) Ta b l e 1. rB C G vacci ne-i nduced pr o t ect i ve e f f i ca cy in th e mo u s e mo d e l V a cci ne gr oupaMe a n lo g 1 0 CF U of M. tu b e rc u l o s i s \u00b1SEM (n = 5 )b Lungp- va l u e com p ar ed to BC G Sp l e e np- va l u e com p ar ed to BC G S a lin e ( C ont r ol ) rB C G / F A rB C G / F BrB C G / B . F A BC G5. 10 \u00b1 0. 21 4. 55 \u00b1 0. 18 * 4. 54 \u00b1 0. 04** 4. 40 \u00b1 0. 18** 4. 48 \u00b1 0. 36*0. 70 0. 72 0. 673. 69 \u00b1 0. 48 3. 36 \u00b1 0. 22 2. 96 \u00b1 0. 22* 3. 13 \u00b1 0. 21* 3. 15 \u00b1 0. 330. 27 0. 31 0. 91 a.C 57B L / 6 mi c e we r e in je c t e d once s u bc ut a n e o us l y wi t h s a lin e ( 2 0 0 l) , BC G , or rB C G s (2 x 105 CF U) . b.Nu m b e r of ba ct er i a is o l a t e d fr o m th e sp l e en an d lu n g 4 we e k s af t e r ae r o s o l c h a lle n g e . *, P < 0 . 05; ** , P < 0 . 001 com p ar ed to cont r o l s (S tu d e n t t- te s t ) .A g 85A (rB C G / F A ), A g 85B (rB C G / F B ), or bo t h ( r BC G / B. FA ) we r e prep ared by tra n s f o r m a ti o n of wi l d - t y p e BC G Pa s t e u r 1173P 2 wi t h re c o m b i n a n t pl a s m i ds cont ai ni ng genes encodi ng th e an t i g e ns wi t h th e i r ow n pr o m ot er s or hs p60 p r om ot er. SD S - PA G E wa s use d to anal yze an d s t ai ni ng of SDS - P A GE ge l wi t h Co o m a s s i e b r illia n t bl u e re v e a l e d al l rB C G s ex pressed and se cr et ed a r e la t i v e ly hi gh le v e l of re c o m b i n a n t Ag 8 5 A , A g 85B , or bot h pr o t e i n s (F i g . 1) . 2. IF N - pr oduct i on of sp l e n o cyt e s IF N - re l e a s e wa s eva l uat e d af t e r in vi t r o st i m ula t i o n wi t h cul t ur e fi l t ra te pr o t ei n( 10 g/ m l ) . Th e re s u l t s of IF N - ELI S A show ed th a t sp l e n o c y t e s fr o m mi c e i mmu n i z e d onl y wi t h rB C G /B . F A co ul d pr o d uce hi g h er IF N - le v e l th a n th o s e fro m th e par e nt al BCG gr o u p (F i g . 2) . 3. Pr o t e c t i v e e f f i ca cy of th e rB C G va cci n e s in th e mo u s e mo d e l BC G and rB C G s - i m m u n i zed mi c e we r e c h a lle n g e d by ae r o so l wi t h M. tu b e r c u l o s i s Er d m a n . Lu n g s an d sp l eens we r e rem o v e d 4 we e k s af t e r c h a lle n g e . An i m a l s i mmu n i z e d wi t h rB C G s or BCG had a fe w e r org a n i s m s in th e lu n g s and sp l eens (e x c e p t th e rB C G /F A gr o u p ) th a n th e sal i n e con t r o l mi c e ( P <0 . 0 5 , St u d e n t t- te s t ) . Th e r e wa s , ho w e ve r , no s i g n ific a n t d i f f er enc e in pr o t ect i ve ef f i cacy bet w een rB C G s an d BC G (T a b l e 1) . D i scussi o n Mo s t of th e candi d at e va c c i n es th a t have been dev e l o pe d ag a i nst TB ha ve per f o r m e d ei t h e r in f e r i o r to BCG or at th e mo s t at par wi t h BC G . Th i s has gi ven a lo t of im p e tu s to th e p r op os al th a t BCG its e l f sh ou l d be dev e l o pe d in t o a mo r e po t e nt va c c i n e. Fo r dev e l o pm ent of an im p r o v e d BCG va c c i n e, sever a l cy t o k i n e ge n e s hav e been expr es se d in re c o m b i n a n t BC G ( r B C G ) sys t em , in an a tte m p t to boost th e Th 1 in d u c i n g a b ilit y of BCG14. It is al so b een su g g e s t e d (10345) (2263) (736)(3258) (63)Tu b e r c u l o s i s and Re s p i r a t o r y Di s e a s e s Vo l . 57. No . 2, Au g , 2004 12 9th a t o v er expr es si o n of i m m u no dom i nant ant i g e ns in BCG ca n al so le a d to im p r o v e d in d u c t io n of Th 1 r e spo n se. Bo t h A g 85A and A g 85B ant i g e ns of M. tu b e r cu l o si s hav e been wi d e l y use d as new va c c i n e ca n di d a t e s agai nst TB . Th e rec e n t fin d in g re p o r t e d by Ho r w i t z and co w o rk ers on th e b e tte r pr o t ec t i ve e ffi ca cy of a re c o m b i n a n t BCG ex pressi ng an ep i t ope ( A g 85B ) of M. tu b e r c u l o s i s co m p ar ed to th e par e nt st r a i n ha ve st r e ngt h ened th e ju s t if ic a t io n fo r us i n g such a st rat e g y . Th e aut h or s sho w ed th a t gui n ea pi g s i mmu n i z e d wi t h th e re c o m b i n a n t BCG and chal l e ng ed wi t h vi r u l e n t M. tu b e r c u l o s i s vi a aer o sol s , had fe w e r baci l l i in th e i r lu n g s and spl e en and s m a lle r and fe w e r le s i o n s in th e s e org a n s as co m p ar ed to th o s e im mu n i z e d wi t h th e par e nt BCG st r a i n s . To dat e , th i s re c o m b i n a n t BCG va c c i n e is th e fir s t va c c i n e rep o rt ed to in d u c e gr eat e r pr o t ect i ve im m u n i ty ag a i nst TB th a n th e st andar d BC G v a cci ne in an an i m al mo d e l15. Al s o , rB C G wh i c h pr o d uc ed la r g e am ount s of Ag 8 5 A enh a nce d th e po t e n t i a l to pr o t ect th e ho st16. Oh a r a et al .17 rep o rt e d th a t rB C G ov erp r od uc i n g A g 85A , Ag 85B , and M P B 51( rB C G / B A 51) red u c e d th e mu l t i p l ic a t io n of M. le p r a e in th e f oot pa ds th a n th a t by par e nt a l BCG. It is expe ct ed th a t th e c o m b in a t io n of sever a l im p o r t a n t pr o t ect i ve ant i gens wo u l d in d u c e st r o ng er pr o t ec t i ve i mmu n i t y in br oad hu m a n po pul a t i on. Th i s st udy de sc r i b e s th re e rB C G s th a t over e x p r e ssed Ag 8 5 A , A g 85B , or bot h . To pr ep ar e rB C G s , we use d th e hsp6 0 p r om ot e r and th e i r ow n pr om ot er s fo r expr es si ng A g 85A , A g 85B , or bot h . Th e rec o m bi nant BC G s s u c c e s s f u lly pr o d uced la r g e am o u nt s of A g 85A and A g 85B . Th e a b ility to pr o d uce IF N - , th e h a llm a r k of a TH1 ty p e of T- c e l l r e spons e , is wi d e l y a ccept ed as a st r o n g co r r el a t e of pro t ec t i v e im m u n i ty to TB18. We fo c u s e d on th is cyt o k i ne res p o n se in th e va c c i n a t e d ani m al s. IF N - le v e ls pr o d uced in r e spons e to cu l t ure fi l t ra t e pr o t ei n of M. tu b e r c u l o s i s we r e hi ghe r in mi c e i mmu n i z e d wi t h rB C G /B . F A th a n in BCG - i mmu n i z e d mi c e , sugg es t i ng th a t rB C G /B . F A enhance th e pr o t ect i ve i mmu n i t y of th e ho st mo r e po t e n t l y th a n BCG. In th e pr o t ect i ve e ffi c a c y ex peri m e nt s, i mmu n i z a t i o n wi t h rB C G /F B or wi t h rB C G /B . F A gav e a 0. 5- lo g red u c t i o n in CFU in th e lu n g s an d sp l eens co m p a r ed wi t h co nt r o l . Ho w e v e r , al t h oug h th e rB C G /B . F A e l ic it e d hi ghe r IF N - le v e l th a n th e i r par e nt al BCG st r a i n , it di dn ' t show gr e a t e r pr ot ect i ve ef f i cacy gr ea t e r th a n th a t of pa r e n t a l BCG ag ai n s t M. tu b e r c u l o s i s in fe c t io n . Th e res u l t s sho w ed th e di f fe re n c e b e t w een im m u n e r e spons e s to an t i g e n s in vi t r o and pr o t ect i ve i mmu n i t y in vi vo . Th e rea s on s are to be ex pl or e d . IF N - is a cen t ral cyt o ki ne in co n t r o l of M. tu b e r cul o si s in fe c t io n . Th i s cy t o k i n e is pr o d uced by bo t h CD4 an d CD8 T cel l s in t uber c ul osi s19- 21 an d is im p o r ta n t in ma c r o p h a g e act i v a t i o n and per h a p s ot her fu n c tio n s . Al t h o u g h IF N - p r oduct i on al one is in s u f fic i e n t to co nt r o l M. tu b e r c u l o s i s in f e c t io n , it is re q u i r e d fo r th e pr o t ect i ve re s p o n s e to th i s pat h ogen. IF N - is pr o d uc ed by T c e lls fro m he al t h y PPD + su bj e c t s as we l l as th o s e wi t h ac t i v e tu b e r c u l o s i s . Al t h o u g h so m e st udi e s sug g es t th a t IF N - le v e ls ar e dep r e s sed in p a ti e n ts wi t h ac t i v e t u ber c ul osi s22, th is cy t o k i n e ma y not be id e a l as an i mmu n e co r r el a t e of pro t ec t i on . Th e re c e n t re p o rt th a t M. tu b e r c u l o s i s has dev e l o pe d me c h a n i s m s to lim i t th e a c ti v a ti o n of ma c r o p h a g e s by IF N - sugg est s th a t th e am ou n t of IF N - pr o d uced by T c e lls ma y be le s s pr edi c t i ve of ou t c om e th a n th e a b ility of th e c e lls to r e spond to th is cy t o k i n e23. Se ver a l app r oa ches ma y be consi d ered fo r fu rth e r enh a ncem ent of th e i m m u no g e ni ci t y an d pr o t ec t i ve ef f i cacy of rB C G va c c i n e : (i ) usi n g shut t l e vec t o r s wi t h hi g h -e f f i c i e ncy p r om ot ers to in c r e a s e expr es si o n of an t i g e n s ; (i i ) addi ng mo r e ki nds of pr o t ec t i ve an t i g e n s , su c h as ES A T -624, CFP 1 0 and M P T 64; ( iii) SH Le e, et al . : Co n s t r u c t i o n of re c o m b i n a n t BC G s ov e r ex pr es s i ng ant i gen 85 co m p l e x and th e i r pr ot ec t i v e 13 0coex pr essi n g ge ne s of cy t o k i n e s , such as IL - 2 , IF N - , and I L - 12( 14) ; and (i v ) u t iliz in g ot h e r me t h o d s of adm i ni st r a t i o n , such as i n t r anasal an d ora l va c ci na t i o n25. So m e schol a r s have pr evi o usl y p r oposed th a t ge ne ti c engi nee r i n g BCG is a ca ndi d at e v a cci ne agai nst TB. De s p i t e th e unsa t i sf act o r y pr o t ect i ve ef f i cacy yi e l d e d in ou r re s e a r c h , th e in c r e a s e d i m m u no g e ni ci t y co m p a r ed wi t h BCG and th e adv a nt a g es of BCG it s e lf ( e .g ., it is sa f e to us e, st abl e to st or e, av a i l a bl e fo r i mmu n i z a t i o n at bi r t h, and co st -ef f e ct i v e) over ot her ty p e s of new va cc i n es ma k e rB C G a ttr a c t i v e in TB v a cci ne de v e l o p m ent . S U MMA R Y 85 ( A g 8 5 A , B, C) . BCG , BCG A , 85 B BCG rB C G , BCG rB C G /B . PA G E , BCG 85A B BCG . M. tu b e r c u l o s i s H3 7 R v cu l t u r e fi l t ra te pr ot ei n ( C F P ) IF N - rB C G /B . F A BCG IF N - , BCG BCG . Re f e r e n c e s 1. Centers for Disease Control and Prevention : D evelo pment of new vaccines for tuberculosis. Recom mendations of the Advisory Council for the Elimi Tuberculosis(ACET). MMWR Recomm Rep. 1998;47:1 -6. 2 . F i n e P E . V a r i a t i o n i n p r o t e c t i o n b y B C G : i m p l i cations of and for heterologous immunity. Lancet 1995;346:1339 -45. 3. Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR Jr, Bloom BR. Auxotrophic vaccines for tuberculosis. Nat Med 1996;2:334 -7. 4. Horwitz MA, Lee BW, Dillon BJ, Horth G. Pro tective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis Pinxteren LA Mang Okkels L, Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and east -6. Infect Immun 2001;69:2773 -8. 7 . H u y g e n K , C o n t e n t J , D e n i s O , M o n t g o m e r y D L , Y a w m a n A M , D e c k R R , e t a l . I m m u n o g e n i c i t y a n d protective efficacy of a tuber culosis DNA vaccine. Nat Med 1996;2:893 -8. 8 .K u m a r P , A m a r a R R , C h a l l u V K , C h a d d a V K , Satchidanandam V. The Apa protein of Mycobac terium tuberculosis stimulates gamma interferon - secreting CD4+ and CD8+ T cells from purified protein derivative -positive individuals and affords protection in a guinea pig model. Infect Immun 2003;71:1927 -37. 9. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994;62:2536 -44. 10. Wiker M. The Drowart Andrien M, Dierckx P, et al. T cell epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun from Mycobacterium bovis bacile Calmette - Gu is associated with pro tective T cells in leprosy: A follow -up study of 45 Tu b e r c u l o s i s and Re s p i r a t o r y Di s e a s e s Vo l . 57. No . 2, Au g , 2004 13 1household contacts. J Infect Dis 1993;167:1160 -7. 1 3 .L e e H Y , C h o S N , K i m H J a n d K i m J D . C o n struction of a Mycobacterium -Escherichia coli shut tle vector and use in the expression of foreign genes i n M y c o b a c t e r i a . T h e J o u r n a l o f t h e K o r e a n S o c i e t y for Microbiology 1997;32:292 -300. 14. Murray PJ, Aldovani A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant 1996;93:934 -9. 1 5 . H o r w i t z M A , H a r t h G , D i l l o n B J , M a s l e s a -Galic S. Recombinant bacillus Calmette Gu \u00e9rin(BCG) vac cines expressing the Mycobacterium tuberculosis 30 -kDa major secretory protein induce greater pro tective immunity against tuberculosis than conven t i o n a l B C G v a c c i n e s i n a h i g h l y s u s c e p t i b l e a n i m a l model. Proc Natl Acad Sci USA 2000;97:13853 -8. 16. Ohara N, Matsuoka M, Nomaguchi H, Naito M, Y a m a d a T . I n h i b i t i o n o f m u l t i p l i c a t i o n o f Mycobac terium leprae in mouse foot pads by recombinant Bacillus -Guerin(BCG). Vaccine 2000;18: 1294 -7. H, Yamada T. Protective responses against experimen tal Mycobacterium leprae infection in mice induced by Calmette -Gu \u00e9rin over -pro ducing three putative protective antigen 2001;19:1906 -10. 18. Ellner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis 2000;30(Suppl.3):S279 - 82.19. O rm e IM , M iller , oberts SK JP, Dobos KM, et al. T Lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. J Immunol 1992;148:189 -96. 2 0 .O r m e I M , R o b e r t s A D , G r i f f i n J P , A b r a m s J S . Cytokine secretion by CD4 T lymphocytes acquired infection. J Immunol -25. R, Wilkinson RJ, AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma -secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl A c a d S c i U S A 1998;95:270 -5. 22. Zhang M, Lin Y, lyer DV, Gong J, Abrams JS, Barnes PF. T cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995;63:3231 -4. 23. Ting LM, Immunol 1999;163:3898 -906. 24. Bao L, Chen W, Zhang H, Wang X. Virulence, im munogenicity, and protective efficacy of two recom binant Mycobacterium bovis bacillus Calmette - Buddle BM. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to "}